W. B. Kannel, R. D. Abbot, D. D. Savage, and P. M. Mcnamara, Epidemiologic features of chronic atrial fibrillation: The framingham study, N Engl J Med, vol.306, pp.1018-1040, 1982.

S. S. Chugh, J. Blacksheart, W. K. Shen, S. G. Hammill, and B. J. Gersh, Epidemiology and natural history of atrial fibrillation: clinical implication, J Am Coll Cardiol, vol.37, pp.371-379, 2001.

C. D. Furberg, B. M. Psaty, J. A. Monalio, J. M. Gardin, and V. E. Smith, Rantaharjin PM for the CHS collaborative research group. Prevalence of the atrial fibrillation in elderly subjects. The cardiovascular heart study, Am J Cardiol, vol.74, pp.236-277, 1994.

P. Fynns, D. M. Todd, J. C. Hobbs, K. L. Armstrong, and C. J. Garratt, Role of dispersion of atrial refractoriness in the recurrence of atrial fibrillation. A manifestation of atrial electrical remondelling in humans?, Eur Heart J, vol.22, pp.1822-1856, 2001.

E. J. Benjamin, P. A. Wolf, D. Agostino, R. B. Silbershatz, H. Kannel et al., Impact of atrial fibrillation on the risk of death: the Framingham Heart Study, Circulation, vol.98, pp.946-952, 1998.

S. Stewart, C. L. Hart, D. J. Hole, and J. J. Mcmurray, A population-based study of the longterm risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/ Paisley study, Am J Med, vol.113, pp.359-364, 2002.

T. Andersson, A. Magnuson, I. L. Bryngelsson, O. Frobert, K. M. Henriksson et al., All-cause mortality in 272,186 patients hospitalized withincident atrial fibrillation 1995-2008: a Swedish nationwide long-term casecontrol study, Eur Heart J, vol.34, pp.1061-1067, 2013.

M. Haissaguerre, P. Jais, D. C. Shah, A. Takahashi, M. Hocini et al., Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins, N Engl J Med, vol.330, pp.659-66, 1998.

C. S. Fox, H. Parise, D. Agostino, R. B. Sr, L. et al., Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring, JAMA, vol.291, pp.2851-2855, 2004.

N. Oyen, M. F. Ranthe, L. Carstensen, H. A. Boyd, M. S. Olesen et al., Familial aggregation of lone atrial fibrillation in young persons, J Am Coll Cardiol, vol.60, pp.917-921, 2012.

P. T. Ellinor, K. L. Lunetta, C. M. Albert, N. L. Glazer, M. D. Ritchie et al., Metaanalysis identifies six new susceptibility loci for atrial fibrillation, vol.44, pp.670-675, 2012.

M. S. Olesen, M. W. Nielsen, S. Haunso, and J. H. Svendsen, Atrial fibrillation: the role of common and rare genetic variants, Eur J Hum Genet, vol.22, pp.297-306, 2014.

M. F. Sinner, N. R. Tucker, K. L. Lunetta, K. Ozaki, J. G. Smith et al., Integrating genetic, transcriptional, and functional analyses to to identify 5 novel genes for atrial fibrillation, Circulation, vol.130, pp.1225-1235, 2014.

D. F. Gudbjartsson, D. O. Arnar, A. Helgadottir, S. Gretarsdottir, H. Holm et al., Variants conferring risk of atrial fibrillation on chromosome 4q25, Nature, vol.448, pp.353-357, 2007.

S. A. Lubitz, K. L. Lunetta, H. Lin, D. E. Arking, S. Trompet et al., Novel genetic markers associate with atrial fibrillation risk in Europeans and Japanese, J Am Coll Cardiol, vol.63, pp.1200-1210, 2014.

M. K. Homoud and M. Estes, Shedding new light on the pathophysiology of conversion of paroxysmal atrial fibrillationinto parsistant atrial fibrillation, Am Heart J, vol.154, pp.801-805, 2007.

M. C. Wijffels, C. J. Kirshhof, R. Dorland, and M. A. Allesie, Atrial fibrillation begets atrial fibrillation. A study in awakechronically instrumented goats, Circulation, vol.92, pp.1454-68, 1995.

M. A. Allesie, P. A. Boyden, A. J. Camm, A. G. Kleber, M. J. Lab et al., Pathophysiology and prevention of atrial fibrillation, Circulation, vol.103, pp.764-77, 2001.

E. Dupont, Y. S. Ko, S. Rothery, S. R. Coppen, M. Baghai et al., The gap junctional prote in connexion. 40 is elevated in patients susceptible to postoperative atrial fibrillation, Circulation, vol.103, pp.842-851, 2001.

M. Paquette, D. Roy, M. Taljic, D. Newman, A. Couturier et al., Role of gender and personality on quality of life impairment in intermittant atrial fibrillation, Am Heart J, vol.118, pp.913-921, 1989.

S. Levy, M. Mareek, P. Coumel, L. Guize, J. Lekieffre et al., The college of French cardiologists. Characterization of different subsets of atrial fibrillation in general practice in France. The ALFA study, Circulation, vol.99, pp.3028-3063, 1999.

K. J. Mukamal, B. M. Psaty, P. M. Rautharju, C. D. Furberg, L. H. Kuller et al., Alcohol consumption and rick and prognosis of atrial fibrillation among older adults: the cardiovascular study, Am Heart J, vol.153, pp.260-266, 2007.

J. Auer, P. Scheibner, T. Mische, W. Langsteger, O. Eber et al., Subclinical hyperthyroidism as a risk factor for atrial fibrillation, Am Heart J, vol.142, pp.838-880, 2001.

A. G. Zaman, A. Archbolt, G. Helft, A. E. Paul, W. P. Cauzen et al., Atrial fibrillation after coronary artery bypass surgery, Circulation, vol.201, pp.1403-1411, 2000.

A. Aizer, J. M. Gaziano, N. R. Cook, J. E. Manson, J. E. Buring et al., Relation of vigorous exercice to risk of atrial fibrillation, Am J Cardiol, vol.103, pp.1572-1579, 2009.

E. P. Waktare, K. Hnatkova, S. M. Sopher, F. D. Murgatryod, X. Guo et al., The role of atrial ectopics in initiatings paroxysmal atrial fibrillation, Eur Heart J, vol.22, pp.333-342, 2001.

P. A. Tunick, L. Mcelhinney, T. Mitchell, and I. Kronzon, The alternation between atrial flutter and atrial fibrillation, Chest, vol.101, pp.34-40, 1992.

M. E. Hamer, W. E. Wilkinson, W. K. Clair, R. L. Page, E. A. Mccarthy et al., Incidence of symptomatic atrial fibrillation in patients with paroxysmal supraventricular tachycardia, J Am Coll Cardiol, vol.25, pp.984-992, 1995.

W. K. Clair, W. E. Wilkinson, E. A. Mccarthy, R. L. Page, and E. L. Pritchett, Spontaneous occurred of symptomatic paroxysmal atrial fibrillation and paroxysmal supra ventricular tachycardia in untreated patients, Circulation, vol.87, pp.1114-1136, 1993.

A. Rosengren, P. J. Hauptman, G. Lappas, L. Olsson, L. Wilhelmsen et al., Big men and atrial fibrillation: effects of body sizeand weight gain on risk of atrial fibrillation in men, Eur Heart J, vol.30, pp.11113-11133, 2009.

P. Kirchhof, S. Benussi, D. Kotecha, A. Ahlsson, D. Atar et al., 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration with EACTS, European Heart Journal, vol.37, issue.38, pp.2893-2962, 2016.

P. Kirchhof, J. Bax, C. Blomstrom-lundquist, H. Calkins, A. J. Camm et al., Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2 nd AFNET-EHRA consensus conference 'research perspectives in AF, Eur Heart J, vol.30, pp.2969-2977, 2009.

K. Guha and T. Mcdonagh, Heart failure epidemiology: European perspective, Curr Cardiol Rev, vol.9, pp.123-127, 2013.

F. Braunschweig, M. R. Cowie, and A. Auricchio, What are the costs of heart failure?, Europace, vol.13, pp.13-17, 2011.

W. P. Wodchis, R. S. Bhatia, K. Leblanc, N. Meshkat, and D. Morra, A review of the cost of atrial fibrillation, Value Health, vol.15, pp.240-248, 2012.

U. Baber, V. J. Howard, J. L. Halperin, E. Z. Soliman, X. Zhang et al., Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial differences in Stroke (REGARDS) Study, Circ Arrhythm Electrophysiol, vol.4, pp.26-32, 2011.

D. Kotecha and J. P. Piccini, Atrial fibrillation in heart failure: what should we do?, Eur Heart J, vol.36, pp.3250-3257, 2015.

M. Anselmino, M. Matta, D. 'ascenzo, F. Bunch, T. J. Schilling et al., Catheter ablation of atrial fibrillation in patients with left ventricular systolic dysfunction: a systematic review and meta-analysis, Circ Arrhythm Electrophysiol, vol.7, pp.1011-1018, 2014.

A. N. Ganesan, S. Nandal, J. Luker, R. K. Pathak, R. Mahajan et al., Catheter ablation of atrial fibrillation in patients with concomitant left ventricular impairment: a systematic review of efficacy and effect on ejection fraction, Heart Lung Circ, vol.24, pp.270-280, 2015.

M. N. Khan, P. Jais, J. Cummings, D. Biase, L. Sanders et al., Pulmonary-vein isolation for atrial fibrillation in patients with heart failure, N Engl J Med, vol.359, pp.1778-1785, 2008.

M. P. Schneider, T. A. Hua, M. Bohm, K. Wachtell, S. E. Kjeldsen et al., Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis, J Am Coll Cardiol, vol.55, pp.2299-2307, 2010.

J. S. Healey, A. Baranchuk, C. E. Morillo, C. A. Garfinkle, M. Yusuf et al., Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a metaanalysis, J Am Coll Cardiol, vol.45, pp.1832-1839, 2005.

M. B. Jibrini, J. Molnar, and R. R. Arora, Prevention of atrial fibrillation by way of abrogation of the reninangiotensin system: a systematic review and meta-analysis, Am J Ther, vol.15, pp.36-43, 2008.

A. H. Madrid, M. G. Bueno, J. M. Rebollo, I. Marin, G. Pena et al., Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study, Circulation, vol.106, pp.331-336, 2002.

K. Ueng, T. Tsai, W. Yu, C. Tsai, M. Lin et al., Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study, Eur Heart J, vol.24, pp.2090-2098, 2003.

A. Vahanian, O. Alfieri, F. Andreotti, M. J. Antunes, G. Baron-esquivias et al., Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on the management of valvular heart disease (version 2012), Eur Heart J, vol.33, pp.2451-2496, 2012.

R. A. Nishimura, C. M. Otto, R. O. Bonow, B. A. Carabello, J. P. Erwin et al., AHA/ ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, vol.63, pp.2438-2488, 2014.

R. Nieuwlaat, A. Capucci, A. J. Camm, S. B. Olsson, D. Andresen et al., Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation, Eur Heart J, vol.26, pp.2422-2434, 2005.

A. Vahanian, O. Alfieri, F. Andreotti, M. J. Antunes, G. Baron-esquivias et al., Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), Eur J Cardiothorac Surg, vol.42, pp.1-44, 2012.

O. Fatemi, E. Yuriditsky, C. Tsioufis, D. Tsachris, T. Morgan et al., Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study), Am J Cardiol, vol.114, pp.1217-1222, 2014.

R. R. Huxley, J. R. Misialek, S. K. Agarwal, L. R. Loehr, E. Z. Soliman et al., Physical activity, obesity, weight change, and risk of atrial fibrillation: the Atherosclerosis Risk in Communities study, Circ Arrhythm Electrophysiol, vol.7, pp.620-625, 2014.

N. F. Murphy, K. Macintyre, S. Stewart, C. L. Hart, D. Hole et al., Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15 000 middle-aged men and women (the Renfrew-Paisley study), Eur Heart J, vol.27, pp.96-106, 2006.

N. Wanahita, F. H. Messerli, S. Bangalore, A. S. Gami, V. K. Somers et al., Atrial fibrillation and obesity-results of a meta-analysis, Am Heart J, vol.155, pp.310-315, 2008.

T. J. Wang, H. Parise, D. Levy, D. Agostino, R. B. Sr et al., Obesity and the risk of new-onset atrial fibrillation, JAMA, vol.292, pp.2471-2477, 2004.

T. F. Overvad, L. H. Rasmussen, F. Skjoth, K. Overvad, G. Y. Lip et al., Body mass index and adverse events in patients with incident atrial fibrillation, Am J Med, vol.126, pp.640-649, 2013.

R. K. Pathak, M. E. Middeldorp, M. Meredith, A. B. Mehta, R. Mahajan et al., Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY), J Am Coll Cardiol, vol.65, pp.2159-2169, 2015.

E. Vizzardi, E. Sciatti, I. Bonadei, D. 'aloia, A. Curnis et al., 58-Digby GC, Baranchuk A. Sleep apnea and atrial fibrillation; 2012 update, J Cardiovasc Med, vol.8, pp.265-272, 2012.

Y. K. Lin, M. S. Lai, Y. C. Chen, C. C. Cheng, J. H. Huang et al., Hypoxia and reoxygenation modulate the arrhythmogenic activity of the pulmonary vein and atrium, Clin Sci (Lond), vol.122, pp.121-132, 2012.

D. Linz, Atrial fibrillation in obstructive sleep apnea: atrial arrhythmogenic substrate of a different sort, Am J Cardiol, vol.110, p.1071, 2012.

V. Roldan, F. Marin, H. Fernandez, S. Manzano-fernandez, P. Gallego et al., Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding), Am J Cardiol, vol.111, pp.1159-1164, 2013.

P. Alonso-coello, V. M. Montori, I. Sola, H. J. Schunemann, P. Devereaux et al., Values and preferences in oral anticoagulation in patients with atrial fibrillation, physicians' and patients' perspectives: protocol for a twophase study, BMC Health Serv Res, vol.8, p.221, 2008.

G. Y. Lip, S. M. Al-khatib, F. G. Cosio, A. Banerjee, I. Savelieva et al., Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches?, J Am Heart Assoc, vol.3, p.1179, 2014.

A. Gorst-rasmussen, F. Skjoth, T. B. Larsen, L. H. Rasmussen, G. Y. Lip et al., Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study, J Thromb Haemost, vol.13, pp.495-504, 2015.

R. G. Hart, L. A. Pearce, and M. I. Aguilar, Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation, Ann Intern Med, vol.147, pp.590-592, 2007.

S. J. Connolly, J. Eikelboom, C. Joyner, H. C. Diener, R. Hart et al., Apixaban in patients with atrial fibrillation, AVERROES Steering Committee Investigators, vol.364, pp.806-817, 2011.

D. S. Frankel, S. E. Parker, L. E. Rosenfeld, and P. B. Gorelick, HRS/NSA 2014 Survey of Atrial Fibrillation and Stroke: Gaps in Knowledge and Perspective, Opportunities for Improvement, Heart Rhythm, vol.12, pp.105-113, 2015.

L. Heuzey, J. Y. Ammentorp, B. Darius, H. , D. Caterina et al., Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry, Thromb Haemost, vol.111, pp.833-841, 2014.

O. 'brien, E. C. Holmes, D. N. Ansell, J. E. Allen, L. A. Hylek et al., Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry, Circ Cardiovasc Qual Outcomes, vol.167, pp.624-631, 2010.

M. Zalesak, K. Siu, K. Francis, C. Yu, H. Alvrtsyan et al., Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin, Circ Cardiovasc Qual Outcomes, vol.6, pp.567-574, 2013.

J. Donze, C. Clair, B. Hug, N. Rodondi, G. Waeber et al., Risk of falls and major bleeds in patients on oral anticoagulation therapy, Am J Med, vol.125, pp.773-778, 2012.

M. Man-son-hing, N. G. Lau, A. Laupacis, and A. , Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls, Arch Intern Med, vol.159, pp.677-685, 1999.

J. Mant, F. D. Hobbs, K. Fletcher, A. Roalfe, D. Fitzmaurice et al., Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial, Lancet, vol.370, pp.493-503, 2007.

H. C. Diener, J. Eikelboom, S. J. Connolly, C. D. Joyner, R. G. Hart et al., AVERROES Steering Committee and Investigators. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial, Lancet Neurol, vol.11, pp.225-231, 2012.

G. Y. Lip, R. Nieuwlaat, R. Pisters, D. A. Lane, and H. J. Crijns, Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation, Chest, vol.137, pp.263-272, 2010.

C. B. Granger, J. H. Alexander, J. J. Mcmurray, R. D. Lopes, E. M. Hylek et al., Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, vol.365, pp.981-992, 2011.

S. J. Connolly, M. D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren et al., RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, vol.361, pp.1139-1151, 2009.

R. P. Giugliano, C. T. Ruff, E. Braunwald, S. A. Murphy, S. D. Wiviott et al., Investigators EA-T. Edoxaban versus warfarin in patients with atrial fibrillation, N Engl J Med, vol.369, pp.2093-2104, 2013.

M. R. Patel, K. W. Mahaffey, J. Garg, G. Pan, D. E. Singer et al., ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, vol.365, pp.883-891, 2011.

D. R. Holmes, S. K. Doshi, S. Kar, M. J. Price, J. M. Sanchez et al., Left Atrial Appendage Closure as an Alternative toWarfarin for Stroke Prevention in Atrial Fibrillation: A PatientLevel Meta-Analysis, J Am Coll Cardiol, vol.65, pp.2614-2623, 2015.

, National Institute for Health and Care Excellence (NICE) guidelines. Atrial fibrillation: management, 2016.

U. Elkayam, Calcium channel blockers in heart failure, Cardiology, vol.89, pp.38-46, 1998.

R. E. Goldstein, S. J. Boccuzzi, D. Cruess, and S. Nattel, Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group, Circulation, vol.83, pp.52-60, 1991.

D. G. Wyse, A. L. Waldo, J. P. Dimarco, M. J. Domanski, Y. Rosenberg et al., A comparison of rate control and rhythm control in patients with atrial fibrillation, N Engl J Med, vol.347, pp.1825-1833, 2002.

I. C. Van-gelder, V. E. Hagens, H. A. Bosker, J. H. Kingma, O. Kamp et al., Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation, N Engl J Med, vol.347, pp.1834-1840, 2002.

G. Opolski, A. Torbicki, D. A. Kosior, M. Szulc, B. Wozakowska-kaplon et al., Investigators of the Polish How to Treat Chronic Atrial Fibrillation Study. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study, Chest, vol.126, pp.476-486, 2004.

M. H. Kong, L. K. Shaw, O. Connor, C. Califf, R. M. Blazing et al., Is rhythmcontrol superior to rate-control in patients with atrial fibrillation and diastolic heart failure?, Ann Noninvasive Electrocardiol, vol.15, pp.209-217, 2010.

D. Kotecha and P. Kirchhof, Rate and rhythm control have comparable effects on mortality and stroke in atrial fibrillation but better data are needed, Evid Based Med, vol.19, pp.222-223, 2014.

R. Dankner, A. Shahar, I. Novikov, U. Agmon, A. Ziv et al., Treatment of stable atrial fibrillation in the emergency department: a population-based comparison of electrical direct-current versus pharmacological cardioversion or conservative management, Cardiology, vol.112, pp.270-278, 2009.

W. S. Chen, B. R. Gao, W. Q. Chen, Z. Z. Li, Z. Y. Xu et al., Comparison of pharmacological and electrical cardioversion in permanent atrial fibrillation after prosthetic cardiac valve replacement: a prospective randomized trial, J Int Med Res, vol.41, pp.1067-1073, 2013.

A. K. Gitt, . Smolkaw, G. Michailov, A. Bernhardt, D. Pittrow et al., Types and outcomes of cardioversion in patients admitted to hospital for atrial fibrillation: results of the German RHYTHM-AF Study, Clin Res Cardiol, vol.102, pp.713-723, 2013.

D. Roy, C. M. Pratt, C. Torp-pedersen, D. G. Wyse, E. Toft et al., Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebocontrolled trial, Circulation, vol.117, pp.1518-1525, 2008.

P. R. Kowey, P. Dorian, L. B. Mitchell, C. M. Pratt, D. Roy et al., Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial, Circ Arrhythm Electrophysiol, vol.2, pp.313-321, 2009.

L. D. Bash, J. L. Buono, G. M. Davies, A. Martin, K. Fahrbach et al., Systematic reviewand meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation, Cardiovasc Drugs Ther, vol.26, pp.167-179, 2012.

P. Chevalier, A. Durand-dubief, H. Burri, M. Cucherat, G. Kirkorian et al., Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis, J Am Coll Cardiol, vol.41, pp.255-262, 2003.
DOI : 10.1016/s0735-1097(02)02705-5

URL : https://doi.org/10.1016/s0735-1097(02)02705-5

P. Alboni, G. L. Botto, N. Baldi, M. Luzi, V. Russo et al., Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach, N Engl J Med, vol.351, pp.2384-2391, 2004.

S. N. Singh, X. C. Tang, D. Reda, B. Singh, K. S. Channer et al., Vernakalantfacilitated electrical cardioversion: comparison of intravenous vernakalant and amiodarone for drug-enhanced electrical cardioversion of atrial fibrillation after failed electrical cardioversion, Systematic electrocardioversion for atrial fibrillation and role of antiarrhythmic drugs: a substudy of the SAFE-T trial, vol.6, pp.51-56, 1999.

M. L. Hansen, R. M. Jepsen, J. B. Olesen, M. H. Ruwald, D. Karasoy et al., Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study), Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study, vol.62, pp.501-507, 2013.

B. Wegscheider, K. Lezius, S. Willems, S. Steven, and D. , Five-year follow-up after catheter ablation of persistent atrial fibrillation using the stepwise approach and prognostic factors for success, Circ Arrhythm Electrophysiol, vol.8, pp.308-317, 2015.

D. Scherr, P. Khairy, S. Miyazaki, V. Aurillac-lavignolle, P. Pascale et al.,

A. Halabi, S. Qintar, M. Hussein, A. Alraies, M. C. Jones et al., Low risk of major complications associated with pulmonary vein antral isolation for atrial fibrillation: results of 500 consecutive ablation procedures in patients with low prevalence of structural heart disease from a single center, Five-year outcome of catheter ablation of persistent atrial fibrillation using termination of atrial fibrillation as a procedural endpoint, vol.8, pp.724-757, 2002.

X. Ma, Y. Zhang, B. Hu, M. Zhu, W. Jiang et al., Left atrial strain is a powerful predictor of atrial fibrillation recurrence after catheter ablation: study of a heterogeneous population with sinus rhythm or atrial fibrillation, Archives of Cardiovascular Diseases, vol.110, issue.4, pp.1008-1022, 2015.

M. Mirza, G. Caracciolo, U. Khan, N. Mori, S. K. Saha et al., Left atrial deformation imaging with ultrasound based two-dimensional speckle-tracking predicts the rate of recurrence of paroxysmal and persistent atrial fibrillation after successful ablation procedures, J Interv Card Electrophysiol, vol.31, pp.247-55, 2011.

H. J. Hwang, E. Y. Choi, S. J. Rhee, B. Joung, B. H. Lee et al., Left atrial strain as predictor of successful outcomes in catheter ablation for atrial fibrillation: a twodimensional myocardial imaging study, J Interv Card Electrophysiol, vol.26, pp.999-1006, 2009.

C. Schneider, R. Malisius, K. Krause, F. Lampe, E. Bahlmann et al., Strain rate imaging for functional quantification of the left atrium: atrial deformation predicts the maintenance of sinus rhythm after catheter ablation of atrial fibrillation, Eur Heart J, vol.29, pp.1397-409, 2008.

D. A. Morris, A. Parwani, and M. Huemer, Clinical significance ofthe assessment of the systolic and diastolic myocardial functionof the left atrium in patients with paroxysmal atrial fibrilla-tion and low CHADS(2) index treated with catheter ablationtherapy, Am J Cardiol, vol.111, pp.1002-1013, 2013.